Cargando…
The Difficult-to-Treat del 17 p Patient—A Case Report in Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) treatment strategies have evolved to include mechanism-driven drugs but now raise new questions regarding their optimum timing and sequencing. In high-risk patients, switching from pathway inhibitors to allogeneic stem cell transplantation (allo-HCT) is still a mat...
Autores principales: | Moldovianu, Ana-Maria, Crisan, Ana Manuela, Varady, Zsofia, Coriu, Daniel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8778873/ https://www.ncbi.nlm.nih.gov/pubmed/35056341 http://dx.doi.org/10.3390/medicina58010033 |
Ejemplares similares
-
Real-World Clinical Outcomes and Adverse Events in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib: A Single-Center Retrospective Study
por: Moldovianu, Ana-Maria, et al.
Publicado: (2023) -
Case Series Using Salvage Haplo-Identical Stem Cells for Secondary Transplantation
por: Ionete, Alexandra, et al.
Publicado: (2023) -
Venetoclax: A Novel Treatment for Patients With del(17p) Chronic Lymphocytic Leukemia
por: Borg, Michelle A., et al.
Publicado: (2017) -
Chronic lymphocytic leukemia with deletion 17p: An Indian scenario
por: Gogia, Ajay, et al.
Publicado: (2019) -
Advances in treating chronic lymphocytic leukemia
por: Tausch, Eugen, et al.
Publicado: (2014)